GlucoTrack, Inc., (GCTK): Price and Financial Metrics
GCTK Price/Volume Stats
| Current price | $0.67 | 52-week high | $1.00 |
| Prev. close | $0.72 | 52-week low | $0.13 |
| Day low | $0.60 | Volume | 248,385 |
| Day high | $0.69 | Avg. volume | 159,378 |
| 50-day MA | $0.33 | Dividend yield | N/A |
| 200-day MA | $0.27 | Market Cap | 17.93M |
GCTK Stock Price Chart Interactive Chart >
GlucoTrack, Inc., (GCTK) Company Bio
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Latest GCTK News From Around the Web
Below are the latest news stories about GLUCOTRACK INC that investors may wish to consider to help them evaluate GCTK as an investment opportunity.
GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTRutherford, NJ, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today it has received a notification letter from Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted an additional 180-day compliance period, or until May 20, 2024, to regain compliance with Nasdaq’s minimum bid price rule. In a notification letter |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the week with a breakdown of the biggest pre-market stock movers traders need to watch on Monday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off Tuesday with a breakdown of all the biggest pre-market stock movers traders need to know about this morning! |
GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATERutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter. To Our Valued Shareholders, As we near the end of 2023, we would like to express our gratitude for your continued support of the Company. We welcome this |
GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITORRutherford, NJ, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has achieved another milestone in its development of an implantable continuous glucose monitor (CGM) by commencing preclinical animal testing. The Company previously announced the completion and positive results of a laboratory-based feasibility study |
GCTK Price Returns
| 1-mo | 110.76% |
| 3-mo | 191.30% |
| 6-mo | 219.05% |
| 1-year | -20.25% |
| 3-year | -74.23% |
| 5-year | N/A |
| YTD | 156.21% |
| 2023 | -81.45% |
| 2022 | -66.19% |
| 2021 | -9.64% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...